IN THE CLAIMS

Please add the following new claims 62-92:

--62. (New) Crystals according to claim 18 wherein up to 5% of the crystals have a particle size of less than 8.23 μm.--

--63. (New) Crystals according to claim 18 wherein up to 5% of the crystals have a particle size of less than 6.67 μm.--

--64. (New) Crystals according to claim 18 wherein up to 5% of the crystals have a particle size of less than 0.82 μm.--

--65. (New) Crystals according to claim 18 wherein up to 10% of the crystals have a particle size of less than 16.54 μm.--

--66. (New) Crystals according to claim 18 wherein up to 10% of the crystals have a particle size of less than 11.97 μm.--

--67. (New) Crystals according to claim 18 wherein up to 10% of the crystals have a particle size of less than 1.19 μm.--

--68. (New) Citalopram hydrobromide crystals wherein up to 50% of the crystals have a particle size of less than 40 μm.--

--69. (New) Citalopram hydrobromide crystals containing crystals having a particle size of less than 5 μm in a proportion of 35% at most.--

--70. (New) The citalopram hydrobromide crystals of claim 69, which comprise crystals having a particle size of not less than 20 μm in a proportion of not less than 10%.--

--71. (New) The citalopram hydrobromide crystals of claim 69, which have an average aspect ratio of not less than 2.0 and not more than 9.0.--

--72. (New) The citalopram hydrobromide crystals of claim 69, which have an average aspect ratio of not less than 2.5 and less than 4.5.--

--73. (New) The citalopram hydrobromide crystals of claim 69, which have an average aspect ratio of not less than 4.5 and not more than 6.0.--

E1 Cont

--74. (New) Citalopram hydrobromide crystals having an average aspect ratio of not less than 2.0 and not more than 9.0.--

--75. (New) Citalopram hydrobromide crystals having an average aspect ratio of not less than 2.5 and less than 4.5.--

--76. (New) Citalopram hydrobromide crystals having an average aspect ratio of not less than 4.5 and not more than 6.0.--

--77. (New) A method of crystallizing citalopram hydrobromide, which comprises the steps of

(a) dissolving citalopram hydrobromide in a solvent system comprising one or more alcohols at a temperature between about 50°C and the refluxing temperature of the solvent system to form a solution, and

(b) cooling the solution to crystallize citalopram hydrobromide while controlling the temperature of the solution.--

--78. (New) The method of claim 77, wherein said controlling step comprises maintaining the temperature of the solution between 20°C and 40°C for a period of time.--

E1 Cont

--79. (New) The method of claim 78, wherein said controlling step comprises maintaining the temperature of the solution between 25°C and 35°C for a period of time. --

--80. (New) The method of claim 77, which comprises cooling the solution at an average rate of 20°C per hour.--

--81. (New) The method of claim 77, which comprises adding a seed crystal of citalopram hydrobromide after cooling said solution to a temperature range of from 20° C to 40°C.--

--82. (New) A method for crystallizing citalopram hydrobromide, which comprises the steps of

(A1) dissolving, by heating, citalopram hydrobromide in a solvent comprising at least one member selected from the group consisting of alcohol having 1 to 3 carbon atoms, water and acetone and

(B1) cooling the resulting product to allow for crystallization while controlling a cooling rate.--

E1 Cont

--83. (New) The method of claim 82, which comprises controlling the cooling rate of the solution in a temperature range of from 0 °C to 80 °C.--

--84. (New) The method of claim 82, which comprises controlling an average cooling rate of the solution in the temperature range of from 20 °C to 40 °C to not less than 30 °C/hour and not more than 60 °C/hour.--

--85. (New) The method of claim 82, which comprises controlling an average cooling rate of the solution in a temperature range of from 20 °C to 40 °C to not less than 0.5 °C/hour and less than 30 °C/hour.--

--86. (New) The method of claim 83, which comprises, after cooling to a temperature range of from not less than 30 °C to less than 48 °C, adding a seed crystal of citalopram hydrobromide for crystallization.--

--87. (New) A method for crystallizing citalopram hydrobromide, which comprises the steps of

(A2) dissolving, by heating, citalopram hydrobromide in a solvent comprising at least one member selected from the group consisting of alcohol having 1 to 3 carbon atoms, water and acetone,

(B2) cooling the obtained solution to achieve crystallization,

(C2) dissolving a part of the obtained crystals by heating, and

(D2) recrystallizing while controlling a cooling rate.--

--88. (New) The method according to claim 87 which comprises cooling to a temperature range of from not less than 30°C to less than 48°C in (B2).--

--89. (New) The method according to claim 87, which comprises, after cooling to a temperature range of from not less than 30°C to less than 48°C, adding a seed crystal of citalopram hydrobromide for crystallization in (B2).--

--90. (New) The method according to claim 87, which comprises dissolving a part of the crystals by heating to not less than 48°C and not more than 60°C in (C2).--